Eosinophil Granule Major Basic Protein, Tissue Biopsy
Also known as: EGMBP TIS
Use
This test is utilized to identify eosinophil activity and involvement in tissues or organs suspected to have eosinophil-related pathophysiology. It employs indirect immunofluorescence to detect cellular localization and extracellular deposition of eosinophil granule core protein (major basic protein 1 [eMBP1]) and/or eosinophil granule matrix protein (eosinophil-derived neurotoxin [EDN]). The results assist in diagnosing eosinophilic esophagitis or other eosinophil-related inflammation as part of the eosinophilic gastrointestinal disease spectrum.
Special Instructions
Not provided.
Limitations
The results of eosinophil granule major basic protein testing may not provide a definitive diagnosis of eosinophilic esophagitis or other eosinophil-related inflammation on their own. Extracellular eMBP1 deposition, though often observed, is not established as a diagnostic feature. Furthermore, small tissue specimens may lead to false positives due to processing artifact. Factors such as patient treatment status and tissue biopsy location can affect results, and findings should be correlated with clinical presentation and histopathological examination of formalin-fixed tissue.
New York Approved
Methodology
Immunoassay (Indirect Immunofluorescence)
Biomarkers
Eosinophil Granule Major Basic Protein 1
Protein
LOINC Codes
- 31208-2 - Specimen source
- 11526-1 - Pathology study
- 10478-6 - EMBP Ag Tiss Ql ImStn
Result Turnaround Time
7-21 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
1 mm
Container
Michel medium (ARUP supply #45462), Zeus tissue fixative, frozen fresh tissue, or formalin-fixed tissue
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 3 weeks |
| Refrigerated | 3 weeks |
| Frozen | Indefinitely |
Other tests from different labs that may be relevant